1-3 of 3
Stephanie R. Land, PhD
Close
Sort by
Journal Articles

Phase II Study of Short Course CHOP-Rituximab Followed by 90-Y Ibritumomab Tiuxetan as First-Line Treatment for Follicular Lymphoma: An Update and Extension of Preliminary Findings on Predictors of Relapse.

Rachel C. Jankowitz, MD, Kenneth A. Foon, MD, The Minh Luong, M.Sc, Stephanie R. Land, PhD, Nicholas A. DeMonaco, MD, Steven H. Swerdlow, MD, Judith Joyce, MD, Jennifer Osborn, MD, Terry Evans, MD, Samuel A. Jacobs, MD
Journal: Blood
Blood (2008) 112 (11): 2001.
https://doi.org/10.1182/blood.V112.11.2001.2001
Published: 2008
Journal Articles

Phase II Trial of Abbreviated CHOP-Rituximab Followed by 90 Y Ibritumomab Tiuxetan (Zevalin) and Rituximab in Patients with Previously-Untreated Follicular Non-Hodgkin Lymphoma (NHL).

Nicholas A. DeMonaco, MD, Michael Wu, MD, Jennifer Osborn, MD, Terry Evans, MD, Kenneth A. Foon, MD, Steven H. Swerdlow, MD, Jeffrey Kant, MD, PhD, Judith Joyce, MD, Stephanie R. Land, PhD, Samuel A. Jacobs, MD
Journal: Blood
Blood (2005) 106 (11): 2449.
https://doi.org/10.1182/blood.V106.11.2449.2449
Published: 2005
Journal Articles

Correlation between Tumor Uptake on Indium-111 Ibritumomab Tiuxetan Imaging and Size on CT to Disease Response on FDG PET/CT Scans Obtained Pre- and Post-Yttrium-90 Ibritumomab Tiuxetan Therapy for Non-Hodgkin Lymphoma.

Jacob M. Alexnder, MD, Judith M. Joyce, MD, Barry M. McCook, MD, Norbert Avril, MD, Stephanie R. Land, PhD, Mirsada Begovic, MD, PhD, Samuel A. Jacobs, MD
Journal: Blood
Blood (2005) 106 (11): 4781.
https://doi.org/10.1182/blood.V106.11.4781.4781
Published: 2005